Like I said, the $XERS non-Gvoke pipeline used to be valued at $0.... probably going to change. https://twitter.com/BioStocks/status/1273586487599280129">https://twitter.com/BioStocks...

Now if I can just convince Biotwitter Legend @semodough to update the $XERS Gvoke prescription data he posted about a month ago....

https://abs.twimg.com/emoji/v2/... draggable="false" alt="🙏🏻" title="Folded hands (heller Hautton)" aria-label="Emoji: Folded hands (heller Hautton)">

$XERS 1/n Here we go.... XERS achieved positive results on its now completed Ph2 trial for XP-3924, released yesterday. This asset has an interesting history that needs to be understood in order to see the value. It has the ability to change the mealtime insulin game.

2/n The $XERS asset is basically $LLY Humulin-R (rapid insulin) plus $AZN Symlin (aka pramlintide) in a single injection.

Pramlintide is what needs the history lesson here. Developed by Oxford, licensed by $AMLN Amylin (sold to $BMY/ $AZN jv, then to AZN)...